glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with thromboplastin in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Trials (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Studies (thromboplastin) | Trials (thromboplastin) | Recent Studies (post-2010) (thromboplastin) |
|---|---|---|---|---|---|
| 162 | 1 | 20 | 10,540 | 281 | 2,126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berdel, WE; Bieker, R; Bremer, C; Kessler, T; Kreuter, M; Mesters, RM; Padró, T; Persigehl, T; Schwöppe, C | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and thromboplastin
| Article | Year |
|---|---|
Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Topics: Animals; Blood Flow Velocity; Endothelium, Vascular; Humans; Immunoenzyme Techniques; Integrin alphaVbeta3; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Recombinant Fusion Proteins; Thromboplastin | 2005 |